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Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the
gastrointestinal tract, accounting for 1e3% of all gastrointestinal malignancies. Throughout the whole
length of the gastrointestinal tract, GISTarises most commonly from the stomach followed by small bowel.
The clinical presentations of GIST are highly variable according to their site and size. The most frequent
symptoms are anemia, weight loss, gastrointestinal bleeding, abdominal pain andmassrelated symptoms.
Patients may present with acute abdomen, obstruction, perforation or rupture and peritonitis. Surgical
resection is the “gold standard” for therapy of GIST. Recently, targeted therapy with inhibitors of tyrosine
kinase receptors (imatinib) has been introduced for the management of advanced and metastatic tumors.
Purpose: The aim of this work is to present the experience of the Gastrointestinal Surgery Unit, Alex-
andria Faculty of Medicine in the management of patients with GIST related emergencies.
Patients and methods: This study was carried out on all patients with gastrointestinal stromal tumors
who presented to the Gastrointestinal Surgery Unit, Main Alexandria University Hospital in an emer-
gency situation during the period from January 2005 till December 2012. All patients’ data, clinical
presentations, radiological and endoscopic data, surgical procedures, complications, and survival data
were collected, reviewed and analyzed. After approval of local ethics committee, all patients included in
the study were informed well about the procedure and an informed written consent was obtained from
every patient before carrying the procedure.
Results: Between January 2005 and December 2012; 92 patients (54males and 38 females) were admitted
with different emergency presentations of clinically and radiologically suspected GISTs. The tumors were
located in the stomach in 49 patients, in the duodenum in 6 patients, in the small intestine in 27 patients, in
the small intestinal mesentery in 4 patients, in the colon in 3 patients and in the rectum in 3 patients. The
most frequent presenting symptom was gastrointestinal bleeding in 45 patients. Twenty-six patients
presented with intestinal obstruction, 14 patients with intraperitoneal hemorrhage and 7 patients with
rupture and peritonitis. Ninety patients were operated upon. Two patients presented with extensive GIST,
and were not candidate for surgical treatment. All operated patients underwent surgical resection. Com-
plete macroscopic resection was achieved in 86 patients (95.6%), while 4 patients (4.4%) had incomplete
resection. All over 11 patients developedmetastases, or recurrence. The 3 and 5-years overall survival rates
for all patients, using the KaplaneMeier actuarial curve, were 92.1% and 81.4% respectively. The 3 and 5-
years disease-free survival rates for all patients were 73.2% and 64.5% respectively.
Conclusion: Although GISTs are uncommon, their incidence is probably increasing especially their emer-
gency presentations. The emergency surgeon must be acquainted with the disease, its emergency pre-
sentation and principles of surgery in the presence of GIST tumors. Early diagnosis and treatment would
save life of many patients who presented with GIST related emergencies. Surgery is still the gold standard
treatment in localized GIST, although the percentage of relapse is not low even after radical surgery. The
prognosis is strictly related to size and completeness of surgical resection. We strongly advocate that all
patients with a GIST be carefully and regularly followed-up for an indeﬁnite period. The large number of
patients in this series is an alarming signal for further studies to elucidate the pathogenesis of this disease.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.ral Surgery, 72 Galal El-Deen
lexandria 002 002, Egypt.
Sorour).
by Elsevier Ltd. All rights reserved.
Table 1
Patients’ characteristics.
Characteristics Number of patients %
Sex:
 Male 54 58.7
 Female 38 41.3
Age: (years)
 Mean  SD 48.15  13.17
 Range 23e72
Clinical presentations
 GIT bleeding 45 48.9
 Intestinal obstruction 26 28.3
 Intraperitoneal bleeding 14 15.2
 Rupture and peritonitis 7 7.6
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Gastrointestinal stromal tumors (GISTs) are the most common
(approximately 80%) mesenchymal tumors of the gastrointestinal
tract, accounting for 1e3% of all gastrointestinal malignancies [1e
4]. These tumors are believed to arise from the interstitial cells of
Cajal (ICC), a complex cellular network thought to act as pacemaker
cells that regulate peristalsis [3,5]. CD117 (c-kit proto-oncogene
product) protein, a tyrosine kinase growth factor receptor, is the
most speciﬁc and important immunochemical marker for GIST [3].
Primary GIST is solitary rather than multiple. Throughout the
whole length of the gastrointestinal tract, GIST arises most
commonly from the stomach (60e70%) followed by small bowel
(20e25%). Less frequent sites include the colon, rectum, esophagus
and appendix. There are also sporadic reports of GIST arising from
the omentum, mesentery and retroperitoneum. GISTs can arise at
any age and are most common in persons between the ages of 40
and 70. They occur with similar frequency in men and women [6e
8].
Morphologically GISTs can be classiﬁed into spindle cell type
(70%), epithelioid type (20%), and mixed type (10%) [6,7]. Grossly,
GISTs are submucosal lesions that appear to arise from the mus-
cularis propria of the bowel wall. Intramural in origin, they often
project exophytic extraluminal and/or endophytic intraluminal,
and they may have overlying mucosal ulceration. Their size can be
extremely variable, from tiny incidental cases to huge masses [9].
Large GISTs nearly always outgrow their vascular supply, leading to
extensive areas of necrosis and hemorrhage [10].
The clinical presentations of GIST are highly variable according
to their site and size. Small tumors are usually incidental ﬁndings
on operation, endoscopy or imaging studies for other reasons. The
most frequent symptoms are anemia, weight loss, GI bleeding,
abdominal pain and mass-related symptoms. Patients may present
with acute abdomen, obstruction, perforation or rupture and
peritonitis. Other presentations include nausea, vomiting, and
abdominal distension [11e13].
DeMatteo et al. reported that metastatic disease was found in
nearly half of their patients. The liver is themost common site (65%)
followed by the peritoneum (21%) whereas lymph nodes, bone and
lung metastases are rare [7].
Surgical resection is the “gold standard” for therapy of GIST. The
primary goal of surgery is complete resection of the disease [9].
However, locally recurrent tumors are usually not amenable to
complete resection because of peritoneal implantation; and hence,
the results of secondary surgery, in the case of recurrent disease, are
generally poor [9]. Survival after complete surgical resection ranges
from 48% to 80% at 5 years. If resection is not complete, only 9% of
patients survive for an average of 12 months [14,15]. Conventional
chemotherapy and radiotherapy are usually ineffective [7,9,16].
Understanding that the molecular pathogenesis of GIST is linked
to deregulated KIT tyrosine-kinase activity has resulted in the
successful application of a novel systemic tyrosine-kinase inhibitor,
imatinib (Gleevec; Novartis Pharmaceuticals Corporation, East
Hanover, NJ), in the treatment of GIST patients with malignant
metastatic or unresectable disease. The use of imatinib at earlier
stages of the disease is only beginning to be investigated, including
the possible role of imatinib as an adjuvant or a neoadjuvant agent
with surgery [17]. New evidence-based treatment guidelines
recommend imatinib as ﬁrst-line therapy in cases of marginally
resectable pathology-conﬁrmed GISTs, with surgery and post-
operative imatinib administration advised if imatinib response
improves resectability [18,19].
The aim of this work is to present the experience of the
Gastrointestinal Surgery Unit, Alexandria Faculty of Medicine in the
management of emergency complications of GIST.2. Patients and methods
Between January 2005 and December 2012; 92 patients (54
males and 38 females) admitted with different emergency pre-
sentations of clinically and radiologically suspected GISTs.
All patients data, clinical presentations, laboratory and radio-
logical investigations, tumor characteristics, pathological ﬁndings,
surgical procedures, intra and postoperative complications, as well
as follow-up and survival data were collected, reviewed and
analyzed.
The tumors were located in the stomach in 49 patients, in the
duodenum in 6 patients, in the small intestine in 27 patients, in the
small intestinal mesentery in 4 patients, in the colon in 3 patients
and in the rectum in 3 patients.
Forty-ﬁve patients presented with gastrointestinal bleeding, 26
patients with intestinal obstruction, 14 patients with intraperito-
neal hemorrhage and 7 patients with rupture and peritonitis.
Upper GI endoscopy with endoscopic biopsy was performed in
41 patients presenting with hematemesis or melena. Colonoscopy
was performed in four patients presenting with fresh bleeding per
rectum.
MSCT scan of the abdomen and pelvis was performed in all the
cases.
Ninety patients were operated upon. All operated patients un-
derwent surgical resection. Histopathological examinations of
surgical specimens and immunohistochemical staining for detec-
tion of c-KIT (CD117) was performed in all cases.
Early and late post-operative complications, recurrence (local
and distant) and mortality were recorded along the follow-up
period. CT scan follow-up examinations were performed in all
cases to detect early recurrences.
Data were presented with numbers, percentage, arithmetic
mean (X) and standard deviation (SD) and were analyzed with SPSS
(version 12.0.1) statistical software. Disease free survival curve and
overall survival curve were estimated using the KaplaneMeier
method.
3. Results
This study included 92 patients who presented with emergency
complications of GIST on clinical, radiological and/or endoscopic
aspects. They were 54 males and 38 females. Their mean age at
diagnosis was 48.15  13.17 years (ranged from 23 to 72 years).
The most frequent presenting symptom was GI bleeding in 45
patients (48.9%), of whom 28 patients had hematemesis and
melena, 13 patients had melena only and four patients had severe
fresh bleeding per rectum. Twenty-six patients (28.3%) presented
with intestinal obstruction. Fourteen patients (15.2%) presented
with intraperitoneal hemorrhage. Seven patients (7.6%) presented
with rupture and peritonitis (Table 1). The GIST originated from the
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from the small intestine in 27 cases (29.3%), from the small intes-
tinal mesentry in 4 cases (4.3%), from the colon in 3 cases (3.3%) and
from the rectum in 3 cases (3.3%) (Table 2, Fig. 1).
Eighty ﬁve patients (92.4%) presented with primary disease
while 7 patients (7.6%) presented with recurrent disease. Patients
with recurrent tumors had their initial tumor located in the small
intestine in 5 patients and in the stomach in 2 patients.
Upper GI endoscopy (UGIE) was performed in 41 patients
(44.6%) who presented with GI bleeding (hematemesis and/or
melena) and where the lesionwas suspected to be within the reach
of the endoscope. UGIE revealed the presence of a gastric lesion in
34 patients and a duodenal lesion in 5 patients and was completely
free in two patients (Fig. 2). UGIE correctly located the lesion in the
duodenum in 5 out of 6 cases with duodenal GIST, two as a large
periampullary tumor, three as a submucosal lesion in the 2nd part
of duodenum, while the 6th lesion was not seen as it was distal in
the 3rd part of duodenum (Fig. 3). UGIE did not show the lesion in
one patient who presented with repeated attacks of melena. This
patient underwent colonoscopy that showed the colonic lesion.
Endoscopic biopsy was performed in 39 patients who showed a
lesion on UGIE, and the true pathological nature of the lesions was
diagnosed in only 27 of them (69%). The pathology report of the
other 12 patients showed different forms of chronic gastritis or
duodenitis as the biopsy was probably taken from the overlying
mucosa.
Colonoscopy was performed in 4 patients who presented with
severe fresh bleeding per rectum. Their preoperative CT scan
showed a rectal lesion in three patients and a sigmoid lesion in one
patient. Colonoscopy showed the lesion in all patients. In one pa-
tient the rectal lesion was felt on PR as a mass extending from the
dentate line up to the middle third rectum. This patient had to be
operated in emergency as his bleeding was profuse and uncon-
trolled by medical treatment. Intra-operative colonoscopy showed
the presence of multiple diverticulae extending up to the cecum
with blood ﬁlling the whole colon and rectum.
CT scan was the most commonly performed imaging tool in this
study, being done for 91 patients. CT was able to detect the lesion in
all the cases, and to locate its site of origin (Fig. 4). CT ﬁndings were
able to suggest the diagnosis of GIST in 75 patients (82.4%) out of 91.
It was not possible to perform a CT scan for a morbidly obese pa-
tient who presented with a huge abdominal swelling and intestinal
obstruction. He had an abdominal US examination that showed the
presence of a large cystic abdominal swelling (30 cm in diameter),
and this was followed by a US guided biopsy that was inconclusive
bringing only necrotic tissue. This patient was then operated to
explore this undeﬁned abdominal swelling.
Ninety patients were operated upon. All operated patients un-
derwent surgical resection. Table 3 and Fig. 5 describe the surgical
procedures performed in relation to the site of the tumor. TwoTable 2
Tumor anatomical location and presentation.
Site Number Presentation
Stomach 49 GIT bleeding (34)
Intra-peritoneal hemorrhage (10)
Peritonitis (5)
Duodenum 6 GIT bleeding
Small intestine 27 Intestinal obstruction (22)
Intra-peritoneal hemorrhage (3)
Peritonitis (2)
SI mesentery 4 Intestinal obstruction
Colon 3 GIT bleeding (2)
Intra-peritoneal hemorrhage (1)
Rectum 3 GIT bleedingpatients presented with advanced GIST, one with invasive gastric
GIST and one with metastatic duodenal GIST and they did not un-
dergo surgical treatment. These two patients underwent ultra-
sound guided biopsy that was conclusive in the two cases and
allowed for the administration of Imatinib (Gleevec).
Complete macroscopic resection was achieved in 86 patients
(95.6%), while 4 patients (4.4%) had incomplete resection. Incom-
plete resection was due to extensive peritoneal deposits in 3 pa-
tients and a huge ﬁxed mesenteric GIST in the 4th patient.
The ﬁrst patient with gastric GIST underwent partial gastrec-
tomy but complete resection of all peritoneal deposits was
impossible. She received postoperative Gleevec therapy.
The second patient with huge mesenteric GIST underwent
incomplete resection as it was ﬁxed to the pancreas and retroper-
itoneal tissue. He received postoperative Gleevec therapy.
The third patient underwent three previous operative pro-
cedures for a recurrent small intestinal GIST. During the last pro-
cedure, extensive abdominal deposits were found involving the
peritoneum, the omentum and the small intestine. Metastasectomy
and resection anastomosis of a small intestinal loop were per-
formed removing as much as possible of the lesions. The post-
operative period was marked by the presence of anastomotic
leakage. Re-operation was performed, and re-resection and
abdominal toilet were done. However, leakage recurred and the
general condition of the patient got worse and she died in the peri-
operative period from multiorgan failure caused by sepsis.
The fourth patient presented with a recurrent small intestinal
GIST with multiple mesenteric and peritoneal deposits. Exploration
was performed and resection of a segment of the small intestine,
with excision of multiple peritoneal and mesenteric lesions was
performed (Fig. 6). The patient had a smooth post-operative period
and was followed for 3 months after surgery and then did not
attend for further follow-up visits.
Seven patients presented with a picture of peritonitis. These
proved on exploration to be a ruptured tumor of the stomach in 5
patients and a ruptured tumor of the small intestine in two patients
with actual peritonitis. Resection of the lesion with safety margin,
peritoneal lavage and toilet were performed. Although, complete
macroscopic resection of the tumor was done, we were not sure
that minute seedlings resulting from the perforation were not left
behind.
Forty-nine patients had gastric GIST. The majority of cases pre-
sented with GIT bleeding (34 cases), followed by intraperitoneal
hemorrhage (10 cases) and rupture and peritonitis (5 cases). Pa-
tients with gastric GIST underwent local gastric wedge resection
(40 patients) to excise the lesion with a 2 cm safety margin (Fig. 7).
Four patients with large gastric GIST underwent total gastrectomy,
two patients underwent partial gastrectomy and two patients un-
derwent partial gastrectomy, splenectomy and distal
pancreatectomy.
Six patients had duodenal GISTs. At surgery, the lesions were
present on the anti-mesenteric border and were discrete and small
in size. After full kocherisation and mobilization of the duodenum,
it was possible to perform a localized wedge resection with direct
closure in 4 patients. The immediate postoperative follow-up was
smooth for these four patients. The 5th patient presented with
repeated attacks of melena and severe anemia. MSCT showed
hypervascular neoplastic mass in the third part of duodenum.
During her hospital stay she suffered from massive bleeding/
rectum and shock. Angiography and pre-operative tumor vessels
embolization were done to save her life. Bleeding stopped after
embolization and she received blood transfusion and underwent
exploration after 5 days. Exploration revealed a localized ischemic
loop of the 4th part of duodenum. Partial duodenectomy was per-
formed using a linear stappler (GIA) followed by a side to side
Fig. 1. Flowchart summarizes the different emergency presentations of GIST and its anatomical location.
Fig. 2. (A, B): Endoscopic pictures of gastric GIST with umbilication and superﬁcial ulcerations.
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(Fig. 8).
Twenty-seven patients had GIST of the small intestine. Twenty-
two cases presented with intestinal obstruction in the form of
intussusception (12 cases, Fig. 9), exophytic and endophytic growth
with lumen obstruction (10 cases, Fig. 10). Three cases presentedFig. 3. (A) Axial CT of the abdomen with oral contrast opacifying the bowel. A sizable mass
The tumor is seen bulging from the second part of the duodenum that is stretched over its a
of the same patient.with intra-peritoneal hemorrhage and two cases with rupture and
peritonitis. Twocases had incomplete resection and their caseswere
already described (vide supra). The remaining 25 patients had their
lesions excised with localized resection of a small intestinal loop.
Four patients presented with lesions of the small intestinal
mesentry. One of them was morbidly obese and his case wasis seen anterior to the right kidney showing faint enhancement with areas of necrosis.
nterior aspect. sizable juxta-ampullary GIST of the duodenum, (B) endoscopic picture
Fig. 4. CT pictures of gastric GISTs. (A) Axial CT with no oral contrast, a sizable mass with central necrosis (liquefaction) is seen bulging into the gastric lumen. (B) Axial CT with oral
contrast opacifying the gastric lumen, a sizable mass is bulging from the anterior aspect of the gastric wall, displacing the stomach and compressing it medially. (C) A similar yet
much smaller mass showing central degeneration compressing the stomach posteriorly.
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cystic lesion (around 30 cm in diameter) was found full of hemor-
rhagic ﬂuid. All patients were treated by resection of the lesion and
its adjoining loop of small intestine (Fig. 11).
Three patients had colonic GIST. One patient presented with
haematemsis and melena as the colonic GIST penetrated into the
duodenum. He underwent segmental resection of both the colon
and duodenum. The other two patients presented with intraperi-
toneal hemorrhage and massive bleeding per rectum respectively.
Both underwent localized resection and primary anastomosis.
Three patients had rectal GIST. Two patients underwent anterior
resection and the third patient had total colectomy and abdomino-
perineal resection with terminal ileostomy for management of his
associated bleeding diverticulae and rectal GIST.
Two patients presented with extensive GIST, and were not
candidate for surgical treatment. The ﬁrst patient had a large exo-
phytic gastric lesion (1518 cm) that was adherent to the pancreas
and transverse colon. The tumor was positive for CD117. The patient
received Gleevec therapy and improved dramatically after 6
months of treatment with disappearance of the associated ascites.
Surgery was proposed to the patient but he refused and did not
attend for further follow-up.
The second patient had a large 7  8  8.4 cm juxta-ampullary
duodenal lesion that was adherent to the posterior wall of the third
part of duodenum and compressing the inferior vena cava (IVC). CT
scan showed multiple focal hepatic lesions. The lesion was positive
for CD117. She received Gleevec therapy. Follow-up CT scan, after 1
year of treatment, showed that the duodenal and hepatic lesions
had become less dense. CT guided biopsy from the hepatic lesions
showed myxomatous degeneration with absence of active tumor
cells (Fig. 12).
Histopathological examination of the 90 resected specimens
settled the diagnosis of GIST in all patients. Some patients pre-
sented with a clinically suspected GIST and were already excluded
from the study as their resected specimens were not diagnosed as
GIST.
The mean tumor size was 9.89  5.42 cm (ranged from 2 to
30 cm). It was less than 5 cm in 35/90 cases (38.9%), 5e10 cm in 38/
90 cases (42.2%), and more than 10 cm in 17/90 cases (18.9%).
The perioperative follow-upwas smooth in 89 patients with few
minimal complications in the form of chest infection (12/
90 ¼ 13.3%), and wound infection (10/90 ¼ 11%) that were treated
conservatively. One patient died in the perioperative period from
multi-organ failure related to sepsis.
Eighty-ﬁve patients only attended to the follow-up visits. The
mean duration of follow-up was 58.43  31.62 months (ranged
from 7 to 80 months).
All over 11 patients (11/90 ¼ 12%) developed metastases, or
recurrence. One patient who presented initially with a primary
large gastric GIST developed liver metastasis 13 months after theoperative procedure and was subsequently managed by Gleevec
therapy (Fig. 13). Two patients who presented initially with recur-
rent gastric GIST, their recurrence occurred at 6 and 11 months
respectively after the operative procedure. The remaining eight had
GISTof the small intestine in seven andmesenteric GIST in one case.
Five of the 7 cases of intestinal GIST presented initially with
recurrent disease. Their recurrences occurred at 6, 7, 13 and 15 and
17 months respectively. Two presented initially with a primary
intestinal GIST and their recurrence occurred at 12 and 18 months
respectively. All the recurrences in these 7 patients were located in
the peritoneum, intestinal mesentery and serosal surface of the
small intestine. Two of them died during the follow-up period at 36
and 80months respectively. The last case withmesenteric GIST was
initially treated with incomplete resection with recurrence after
one month and received Gleevec therapy.
The 3 and 5-years overall survival (OS) rates for all patients,
using the KaplaneMeier actuarial curve, were 92.1% and 81.4%
respectively. The 3 and 5-years disease free survival (DFS) rates for
all patients were 73.2% and 64.5% respectively.
4. Discussion
This study included 92 patients (54males and 38 females). Their
mean age at diagnosis was 48.15  13.17 years (ranged from 23 to
72 years). Cavaliere et al. [9] reported that GIST can arise at any age,
with a peak around 60 years, and that they affect males and females
equally. Miettinen et al. [20] stated that GISTs are rare before the
age of 40 years and very rare in children. Miettinen et al. [20] and
DeMatteo et al. [21] reported a slight male predominance; however
other reports showed no sex difference [5].
The symptoms associated with primary GIST are usually vague
and non speciﬁc and depend on the size and location of the lesion
[22,23]. Incidental discovery accounts for approximately one third
of cases [23]. The most common symptoms are GI bleeding in 50%
of patients, abdominal pain in 20e50%, GI obstruction in 10e30%,
and may be asymptomatic in 20% [23]. Other rare presentations
include biliary obstruction, dysphagia, intussusception, and hypo-
glycemia [24e27]. In our series which is concerned with emer-
gency cases only, the most frequent presenting symptom was GI
bleeding in 45 patients (48.9%). Twenty-six patients (28.3%) pre-
sented with intestinal obstruction. Fourteen patients (15.2%) pre-
sented with intraperitoneal hemorrhage. Seven patients (7.6%)
presented with rupture and peritonitis.
Spontaneous rupture of gastric GISToccurs infrequently, and the
most common site of rupture of these tumors is the GI lumen [28].
However, tumor rupture causing massive intraabdominal bleeding
and peritonitis were also reported [29e31]. Recently, John et al.
have reported an unusual case of gastric GIST who presented as
intratumoral bleeding documented by angiography [32]. Cruz RJ
et al. have reported a rare presentation of intratumoral bleeding
Table 3
Surgical procedures in relation to the site of tumor.
Site Surgical procedure Completeness of resection
Stomach (49) Wedge resection (40)
Total gastrectomy (4)
Partial gastrectomy (2)
Partial gastrectomy,
splenectomy and distal
pancreatectomy (2)
Irresectable (1)
Complete
Complete
1 complete, 1 incomplete
Complete
No surgical procedure
Duodenum (6) Wedge resection (4)
Partial duodenectomy (1)
Irresectable (1)
Complete
Complete
No surgical procedure
Small intestine (27) Localized resection Complete (25)
Incomplete (2)
Mesentery (4) Resection þ segmental
intestinal resection
Complete (3)
Incomplete (1)
Colon (3) Resection Complete
Rectum (3) Anterior resection (2)
Total colectomy and
abdomino-perineal
resection with terminal
ileostomy (1)
Complete
Complete
M.A. Sorour et al. / International Journal of Surgery 12 (2014) 269e280274
ORIGINAL RESEARCHfollowed by intraluminal rupture of a giant gastric GIST resulting in
upper GI bleeding [33]. In view of the exophytic nature of the
growth, intestinal obstruction occurs due to compression rather
than luminal obstruction. As such intestinal obstruction is a rare
occurrence until the tumor attains enormous size. Cappellani et al.
have reported a case of a very large GIST of the stomach with bowel
obstruction due to left colic ﬂexure compression [34].
Perforation is usually attributed to replacement of bowel wall by
tumor cells, tumor embolization leading to ischemia, necrosis
together with raised intra-luminal pressure [35e37]. Perforation of
the tumor lowers the ﬁve-year survival to 24%, probably due to
peritoneal dissemination [36]. Roy et al. have reported a case of
spontaneous perforation of a jejunal gastrointestinal stromal tumor
[38]. Sreevathsa MR has reported a case of caecal GIST with
perforation managed by right hemicolectomy, omentectomy and
peritoneal lavage with a diagnosis of perforated carcinoma of
cecum. Histopathology of the resected specimen revealed a high
grade caecal GIST [39]. Adjuvant therapy with imatinib in perfo-
rated GIST is recommended [40,41]. Closed loop obstruction with
perforation of cecum secondary to GIST of splenic ﬂexure has been
reported [42]. Goyal R et al. have reported a case of a large pero-
rated GIST of Meckel’s diverticulum with peritonitis [43].
Upper GIT endoscopy usually shows the lesion, when accessible,
as a submucosal mass with or without ulceration. Endoscopic ul-
trasonography (EUS), if available should be performed, especially
for small lesions less than 2 cm. EUS can delineate the lesion, deﬁne
its layer of origin and can guide the biopsy. In our series, upper GI
endoscopy (UGIE) was performed in 41 patients (44.6%). These
patients presented with GI bleeding (hematemesis and/or melena),
where the lesion was suspected to be within the reach of the
endoscope. UGIE revealed the presence of a gastric lesion in 34
patients and a duodenal lesion in 5 patients and was completely
free in two patients. In one patient the lesion was distal in the 3rd
part of duodenum beyond the reach of the endoscope and in the
remaining patient who presented with repeated attacks of melena,
the lesionwas seen in the colon by colonoscopy. Endoscopic biopsy
was performed in 39 patients who showed a lesion on UGIE, and
the true pathological nature of the lesions was diagnosed in only 27
of them (69%). The pathology report of the other 12 patients
showed different forms of chronic gastritis or duodenitis as the
biopsy was probably taken from the overlying mucosa. This is in
accordance with the ﬁndings of Cavaliere et al. [9] and El-Zoheiryet al. [22] who reported that the endoscopic biopsy was diag-
nostic in 57.14% and 33.3% of their patients respectively.
CT scan was the most commonly performed imaging tool in this
study, being done for 91 patients. CT was able to detect the lesion in
all the cases, and to locate its site of origin. CT ﬁndings were able to
suggest the diagnosis of GIST in 75 patients (82.4%) out of 91. El-
Zoheiry et al. [22] noted that CT was most useful in terms of
demonstrating a mass lesion, determining its size and its relation to
the contiguous organs. Lau S et al. [44] stated that CT is the most
common imaging technique used to assess distant metastases from
GIST, and it should, unless emergency surgery is indicated, be
performed pre-operatively to accurately stage GIST.
We performed US guided biopsy in 2 patients presenting with
invasive gastric GIST in one, and metastatic duodenal GIST to the
liver in the other. The needle biopsy was conclusive in these two
cases and allowed for the administration of targeted therapy by
imatinib (Gleevec). Connolly et al. [45] stated that percutaneous
(US or CT) or laparoscopically-guided biopsies should not be used in
resectable disease due to risk of tumor rupture or seeding. It is only
indicated in clearly irresectable disease and when it may result in a
change of treatment, as would be the case if the mass proved to be
lymphoma [46].
GISTs may arise anywhere in the tubular GI tract, from the
esophagus to the rectum [3]. In our series, the stomach was the
most common organ from which tumors originated (53.3%), fol-
lowed by the small intestine (29.3%), duodenum (6.5%), mesentery
(4.3%), colon and rectum (3.3% each). This is in accordance with
most of the ﬁndings reported by the different series in the literature
[3,47].
In our study, ninety patients underwent surgery. Two patients
received Gleevec as they had advanced disease. Cavaliere et al. [9]
stated that the preoperative diagnosis of GIST is difﬁcult, mainly
due to non speciﬁc symptoms, and that it can be formally made
only by the pathologist on the excised tumor. Immunohistochem-
ical analysis of c-Kit expression and morphological examination
allows the correct identiﬁcation of GIST and the differential diag-
nosis with the other mesenchymal, neural and neuroendocrine
neoplasms occurring in the abdomen. Thus, this study included
only 92 patients with the deﬁnite diagnosis of GIST that had their
results analyzed.
At the time of presentation, eighty ﬁve patients (92.4%) pre-
sented with primary disease while 7 patients (7.6%) presented with
recurrent disease. Patients with recurrent tumors had their initial
tumor located in the small intestine in 5 patients and in the
stomach in 2 patients. Two patients had irresectable GISTs, one
with invasive gastric GIST and one with metastatic duodenal GIST
to the liver. Complete macroscopic resection was achieved in 86
patients (95.6%), while 4 patients (4.4%) had incomplete resection.
The ﬁrst case presented with gastric GIST with peritoneal deposits,
the second with huge mesenteric GIST ﬁxed to the retroperitoneal
tissue, the remaining two patients with recurrent small intestinal
GIST and peritoneal and omental deposits. DeMatteo et al. [7] in a
retrospective analysis of 200 patients with GIST who underwent
surgery, found that in 46% of the cases the tumor was conﬁned, in
47% it was already metastatic at diagnosis, and in 7% it was locally
invasive. The most frequent metastatic sites were the liver (50%)
and peritoneum (20%), while lymph nodes and extra-abdominal
sites are rarely involved [48]. In our series, one patient had
metastasis to the liver, and 5 patients had metastasis to the
peritoneum.
Ninety of our 92 patients (97.8%) with GIST underwent surgery.
Many authors in the literature conﬁrm that surgical resection is still
“the gold standard treatment” for GISTs, especially when localized,
allowing to reach a cumulative 3e5 years survival of almost 50 to
30% respectively [22,49,50,51]. The primary goal of surgery is
Fig. 5. Flowchart summarizes the different surgical procedures performed and outcome in relation to the site of GIST.
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rupture as this is considered a poor prognostic factor [14]. We agree
with El-Zoheiry et al. [22] that achieving negative pathologic
margins of resection is generally not difﬁcult because GIST tends to
hang from, not diffusely inﬁltrate, the organ of origin. Several re-
views have reported that small GIST can be treated adequately by
wedge (gastric) or segmental (bowel) resection [52] and more
extensive surgery has no better beneﬁt [22]. However, larger GIST
may require more extensive en bloc resection including adjacent
structures or organs if involved [48,52]. GIST, even with high ma-
lignant potential, rarely metastasizes to lymph nodes to warrant
lymph node dissection [46,52,53]. In our series, therewas no lymph
node involvement and no extended lymph node dissection was
performed.
In our study, complete macroscopic resectionwas possible in 86
patients (95.6%), and resection was considered incomplete in 4
patients (4.4%). Boni et al. [51] reported that macroscopicallycomplete resection was possible in 84% of their cases and found
that the presence of residual tumor was signiﬁcantly related to
early recurrence and short survival.
In our series, the 3 and 5-years disease free survival (DFS) rates
for all patients were 73.2% and 64.5% respectively, while none of the
patients with incomplete resection was disease free at 3 years
postoperative follow-up. Pierie et al. [16] and DeMatteo et al. [7]
found a signiﬁcantly longer survival rate when GISTs were
completely removed (42% versus 9%). Lin SC et al. [10] reported that
the 5-year survival after complete resection was 73%, while it was
26% after incomplete resection, and this difference was statistically
signiﬁcant.
The potential biological behavior of GIST is difﬁcult to predict.
The Consensus Guidelines for GIST prognosis, supported by the
National Institute of health, suggest that mitotic index and tumor
size are the most effective prognostic factors [3,54]. These ﬁndings
allowed Fletcher et al. [3] to combine these criteria in a new scale
Fig. 5. (continued).
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size and HPF mitotic count.
The mean tumor size in our series was 9.89  5.42 cm (ranged
from 2 to 30 cm). It was less than 5 cm in 35/90 cases (38.9%), 5e
10 cm in 38/90 cases (42.2%), and more than 10 cm in 17/90 cases
(18.9%). Lin SC et al. [10] reported a mean tumor size of 7.5 5.7 cm
while Bucher et al. [55] reported a median tumor size of 5 (range
0.5e26) cm. Lin SC et al. [10] reported that 43% of their patients had
tumors more than 5 cm and that 57% were less than 5 cm. Lin SC
et al. [10] reported a 5-year survival of 78% for patients with tumors
between 2 and 5 cm, 57% for those with tumors between 5 and
10 cm, and 27% for those with tumors larger than 10 cm (P< 0.001).
Boni et al. [51] found that patients with GIST less than 5 cm had a
signiﬁcantly longer survival than patients with bigger tumors.Katharine et al. [56] found that tumor size had a signiﬁcant impact
on overall survival as tumors 5 cm or larger in size had a 28-month
median survival, while those that were less than 5 cm had a 42-
month median survival.
Although surgery is the gold standard in localized GIST, the
percentage of relapse is not low even after radical surgery. Low and
intermediate-risk patients generally have a good outcome following
surgery, whereas high-risk tumors usually recur after resection, and
the results of secondary surgery are generally poor. Our results
coincide with the latter statement, as the 7 patients in our series
who presented initially with recurrent disease got several episodes
of recurrence and two of them died during the follow-up period.
Patients with advanced GISTs usually face severe morbidity and
short life expectancy. The median overall survival for unresectable
Fig. 6. (AeE): The resected specimens during the subsequent operation for treatment of a recurrent small intestinal GIST.
Fig. 7. Wedge resection of a gastric GIST.
Fig. 8. (A) Axial CT of a MSCT showed vividly enhancing duodenal neoplastic mass. (B) Maximum intensity projection (MIP) reformatted image showing the superior mesenteric
artery (SMA) and its major branches. Parts of the hepatic and gastro-duodenal artery are also seen in the same image. (C & D) A 5 fr catheter is inserted in the GDA (selective digital
subtraction angiography). A faint rather abnormal blush is seen in the mass just posterior to the main stem of the SMA. Embolization was performed to stop the bleeding. (E & F)
Exploration and partial duodenectomy.
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Fig. 9. (A, B): (A) GIST in the terminal part of the jejunum causing jejuno-ileal intussusception. (B) GIST of the terminal ileum causing ileo-colic intussusception.
Fig. 10. (A) Axial view of the CT, showing a vividly enhancing tumor (GIST) related to the terminal ileal loops. The bowel loops proximal to the mass are markedly distended with
ﬂuid, while the loops distal to it are collapsed, indicating intestinal obstruction. (B) Resection of ileal GIST.
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months), and 9e12 months for patients with local recurrence
[22,46,57]. Themanagement of unresectable peritoneal and hepatic
metastases from GISTs has been a challenging problem since ma-
lignant GISTs are refractory to conventional cytotoxic therapy [58].
Also the use of radiation has been limited because the dose of ra-
diation required to control GIST is likely to exceed the tolerance of
surrounding tissues [59]. Consequently, radiation therapy is not
considered to be a viable treatment option, except in selected cases
of rectal GISTs where it seems to be indicated only to prevent local
recurrence [16,51].
In case of advanced or relapseddisease, newhopes are nowgiven
by the target therapy against the tyrosine kinase receptor c-Kit. TheFig. 11. (A) CT showing a huge soft tissue mass lesion showing heterogenous pattern of enh
bowel loops around its bulk. (B,C) Resection of jejunal GIST.clinical activity in GISTof the c-kit-targeting drug STI-571(Imatinib-
Gleevec) has been conﬁrmed in phase I and in phase II studies
[18,60], and it is possible that it will improve the outcome of pro-
gressed or relapsed CD117-positive GISTs and of those cases which
cannot undergo radical surgery. Rarely, KIT negative GIST can
respond toGleevec and this canbe explainedon the basis of platelet-
derived growth factor receptor (PDGFRA) mutations.
Finally, the conclusive evidence of a deﬁnitive response of
advanced GIST to Gleevec was demonstrated by a pivotal ran-
domized multicentre trial. This study showed that, 84% of the pa-
tients derived clinical beneﬁt from Gleevec therapy (complete
response 1%, partial response 67% or stable disease 16%). Median
time to achieve complete response or partial response was 13ancement, located in the left lumbar region and displacing and stretching the adjacent
Fig. 12. A known patient with peri-ampullary duodenal GIST. (A) Axial CT image showing liver deposits with ring like enhancement (target sign). (B) After administration of
Gleevec, follow up CT at the same level showing liver deposits showing good response where the lesion became markedly hypodense with absent enhancement (almost cystic)
indicating massive necrosis and breakdown.
Fig. 13. Large gastric GIST and liver metastases. (A) Axial CT image showing extensive liver deposits with heterogenous enhancement and areas of necrosis. (B) After administration
of Gleevec, CT at the same level showing liver near complete disappearance (vanishing) of the deposits with tiny scars remaining.
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for unresectable and/or metastatic GISTs that affects the natural
history of the disease. In addition, Gleevec increases survival in
patients with metastatic and/or unresectable GISTs, in comparison
with historical treatment [55].
DeMatteo et al. [7] in 200 patients found no correlation between
tumor’s site of origin and survival. Opposite results have been re-
ported by Lillemoe et al. [62] in 133 resected GIST, where survival
was, indeed in relationship with tumor’s site. Fletcher et al. [3]
stated that more recent data suggest that anatomic location is a
prognostic factor independent of tumor size, mitotic rate, and pa-
tient’s age, with a trend for small bowel tumors to have the worst
prognosis and esophageal tumors the best, but the basis for these
differences remains uncertain [63]. Our results coincide with those
of Lin SC et al. [10] who found that most of their patients with small
intestinal GIST had lesions larger than 5 cm and a poorer outcome
than those with gastric tumors. In our study, 7 of the 11 patients
who developed recurrence and metastases had their initial tumor
originating from the small intestine, as well as two of them died.
Yan H et al. [64] found that GISTs are four times more likely to recur
if the primary site is the intestine compared with stomach.5. Conclusion
Although GISTs are uncommon, their incidence is probably
increasing especially their emergency presentations. The diagnosis
of GIST should be kept in mind during the work up of patients
presented with GIT bleeding, intestinal obstruction, intraperitoneal
hemorrhage or peritonitis. Early diagnosis and treatment wouldsave life of many patients who presented with GIST related emer-
gencies. The emergency surgeon must be acquainted with the
disease, its emergency presentation and principles of surgery in the
presence of GIST tumors. Surgery is still the gold standard treat-
ment in localized GIST, although the percentage of relapse is not
low even after radical surgery. The prognosis is strictly related to
size and completeness of surgical resection. We strongly advocate
that all patients with a GIST be carefully and regularly followed-up
for an indeﬁnite period. Two recent developments are important
with regard to GIST. The ﬁrst is the ability to diagnose the tumor
based on immunohistochemical staining for KIT (CD117). The sec-
ond is the development of Imatinib (Gleevec), which speciﬁcally
targets CD117, providing a new tool to combat metastatic and
recurrent GIST. The large number of patients in this series is an
alarming signal for further studies to elucidate the pathogenesis of
this disease.References
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